BRANMOOR
THURSDAY · 14 MAY 2026

FDA Recall D-0182-2023

Glaxosmithkline Consumer Healthcare Holdings DBA Haleon · Warren, NJ

Class I — life-threatening Terminated 447 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.

Product

Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Distributed by: Pfizer, Madison, NJ 07940, UPC 3 0573 0169 49 3

Lot / code: Lot: R94065, Exp 02/29/2024

Quantity: 88,380 capsules

Reason for recall

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Recall record

Recall number
D-0182-2023
Classification
Class I
Status
Terminated
Voluntary or mandated
Voluntary: Firm initiated
Firm notification
Letter
Distribution
Nationwide in the USA.
Recall initiated
2022-12-06
Classified by FDA Center
2023-01-25
FDA published
2023-02-01
Terminated
2024-02-26
Recalling firm
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
Firm location
Warren, NJ

‹ All recalls